Climb Bio Announces Participation in Major Investor Conferences
Climb Bio, Inc. (NASDAQ: CLYM), a pioneering clinical-stage biotechnology enterprise, has revealed that key members of its executive team will participate in several upcoming investor conferences, showcasing the company's dedication to transparency and engagement with the investment community.
Upcoming Conferences
These conferences are platforms for Climb Bio to present insights about its innovative work in the realm of biotechnology, particularly in developing treatments for immune-mediated diseases. Here are the major conferences where Climb Bio will be present:
Guggenheim Securities Healthcare Innovation Conference
The company will feature as part of a fireside chat and has arranged one-on-one investor meetings to promote interaction and feedback. This conference will occur on November 11-12, highlighting cutting-edge advancements in healthcare and biotechnology.
Stifel 2024 Healthcare Conference
This event, taking place on November 18-19, will also consist of a fireside chat and personalized meetings. It serves as another vital opportunity for the company to connect with investors and provide updates on its ongoing projects.
36th Annual Piper Sandler Healthcare Conference
Scheduled for December 3-5, this esteemed gathering will facilitate discussions on various healthcare innovations. The interactive format will include both a fireside chat and individual meetings, fostering a deeper understanding of Climb Bio's objectives and strategies.
7th Annual Evercore ISI HealthCONx Conference
During the same dates as the Piper Sandler event, Climb Bio will again engage with potential investors. This double presentation is a strategic move aimed at maximizing exposure and interaction with the investment community.
Webcast and Presentation Details
All conference presentations will be professionally webcast live. For those unable to attend, recordings will be accessible under the "News & Events" section of Climb Bio's website. This approach ensures that all interested parties can stay informed about the company’s progress.
About Climb Bio, Inc.
Climb Bio, Inc. focuses on revolutionizing treatments for various immune-mediated conditions. One of its standout offerings, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete B-cells and has shown promise in addressing a wide range of B-cell mediated diseases. Climb Bio is committed to advancing therapeutic solutions that improve patient outcomes and enhance quality of life.
Investor and Media Relations
For those interested in engaging further with Climb Bio, the company has made its investor relations personnel available. Chris Brinzey, from ICR Healthcare, is the point of contact for investor inquiries. He can be reached at 339-970-2843 or via email for further information. In addition, media inquiries can be directed to Jon Yu, also from ICR Healthcare, at 475-395-5375.
Frequently Asked Questions
What is Climb Bio's primary focus?
Climb Bio focuses on developing innovative therapeutics for patients with immune-mediated diseases.
Where can I find Climb Bio's conference presentations?
You can find their presentations available for replay in the "News & Events" section of their website.
Who can I contact for investor relations inquiries?
Chris Brinzey from ICR Healthcare is the contact person for investor inquiries.
What is budoprutug?
Budoprutug is an anti-CD19 monoclonal antibody candidate developed by Climb Bio, aimed at treating a variety of B-cell mediated diseases.
When are the upcoming investor conferences?
The upcoming conferences are scheduled for November and December, including the Guggenheim and Stifel conferences in November and the Piper Sandler and Evercore conferences in December.